好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A 18F-FDG-PET Study on Brain Metabolic Correlates of King’s Staging System in ALS
Neuromuscular and Clinical Neurophysiology (EMG)
S18 - Neuromuscular and Clinical Neurophysiology (EMG): Neuroimaging, Outcome Measures, and Biomarkers (1:24 PM-1:36 PM)
003

To assess the brain 18F-FDG-PET metabolic changes related to King’s stages in ALS.

Pathological studies have supported the concept of ALS spreading by corticofugal propagation. The King’s staging system (KSS) reflects the extent of involvement in different body regions, and represents a proxy of the diffusion of lesions in the CNS in ALS.

A total of 390 ALS cases with KSS 1, 2 or 3 seen at the ALS Centre of Turin, Italy, in the period 2008-2015 underwent brain 18F-FDG-PET at diagnosis. KSS was regressed against brain metabolism using the multiple regression model of SPM 12. Two-sample t-test was used for group comparisons. Age at PET and sex were included as covariates in all the analyses (height threshold p<0.001; p<0.05 FWEcorrected at cluster level).

In the multiple regression analysis brain metabolism correlated negatively with KSS (KSS 1, relatively highest metabolism; KSS 3, relatively lowest metabolism) in bilateral medial frontal gyrus (BA6), right precentral gyrus (BA4), and right postcentral gyrus (BA2). No significant positive correlation (hypermetabolic areas) was found. The comparison between the group with KSS 1 and the group with KSS2 revealed no significant difference. Comparing KSS 1+2 vs KSS 3 we found a significant relative hypometabolism in the KSS 3 group in left precentral and medial frontal gyrus (BAs 4 and 6), and right precentral, middle frontal, postcentral, and medial frontal gyrus (BAs 4, 6, 3, 9, and 8). No clusters of relative hypermetabolism were found.

With the increase of KSS, we found a decreasing gradient of metabolism in motor areas, with the involment of extramotor regions. Our findings support the hypothesis that that the neurodegenerative process of ALS tends to spread from the motor cortex to posterior and anterior regions in an ordinate sequence.


Authors/Disclosures
Adriano Chio, MD, FAAN (Dept. of Neuroscience, University of Turin)
PRESENTER
Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept.
No disclosure on file
Andrea Calvo, MD, PhD, FAAN (Dept. of Neuroscience, University of Turin) Dr. Calvo has nothing to disclose.
Cristina Moglia (University of Torino) Cristina Moglia has nothing to disclose.
Umberto Manera, MD (Department of Neuroscience "Rita Levi Montalcini" - University of Torino) Dr. Manera has nothing to disclose.
Rosario Vasta, MD (University of Turin, Department of Neurosciences) Dr. Vasta has nothing to disclose.
Maurizio Grassano, MD (Dept. of Neuroscience, University of Turin) Dr. Grassano has received research support from American Brain Foundation, ALS Association and 好色先生.
No disclosure on file
Alessandro Bombaci, MD (Rita Levi Montalcini Department of Neuroscience, University of Turin) Dr. Bombaci has nothing to disclose.
Antonio Canosa Antonio Canosa has nothing to disclose.